Roche Holding AG raised its 2024 profit forecast as new drugs like Vabysmo for eye disease drove revenue for the latest quarter and first half of the year.
Adjusted earnings per share for 2024 will increase in a high-single-digit percentage range at constant exchange rates, the drugmaker said Thursday in a statementBloomberg Terminal. Roche had earlier forecast a mid-single-digit percentage increase.